Search - tctmd.com

Displaying 201 - 220 of 273

Sort: Relevancy | Date

Presentation TCT 2016

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Presenter: Patrick T. O'Gara, Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Animal Testing: FDA Expectations

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Natalie Miller

October 30, 2016

Presentation TCT 2016

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Presenter: Felix Mahfoud, Michael A. Weber, Ehtisham Mahmud

October 30, 2016

Presentation TCT 2016

Points To Consider in the Review of Endovascular Treatment Devices: Japanese Regulatory View

Presenter: Schuyler Jones, Misti Malone, Shin Iwamoto

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Atherectomy

Presenter: Schuyler Jones, Misti Malone, Brad Martinsen, PhD

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Presenter: Felix Mahfoud, Michael A. Weber

October 30, 2016

Presentation TCT 2016

Introduction to the TCT 2016 Peripheral Vascular Intervention Sessions

Presenter: D. Christopher Metzger, Constantino S. Pena, Michael R. Jaff

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Drug-Coated Balloons

Presenter: Schuyler Jones, Misti Malone, George Papandreou

October 30, 2016

Presentation TCT 2016

Japan Academia View

Presenter: Schuyler Jones, Misti Malone, Hiroyoshi Yokoi

October 30, 2016

Presentation TCT 2016

US Academia View

Presenter: Schuyler Jones, Misti Malone, Michael R. Jaff

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Poor Femoral Access

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Richard Smalling

October 30, 2016

Presentation TCT 2016

Severe AS and Extreme Co-morbidities (Futile Patient?)

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Suzanne V. Arnold

October 30, 2016

Presentation TCT 2016

Management of Failing Aortic Bioprosthesis

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Danny Dvir

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Atrial Fibrillation

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Fabian Nietlispach

October 30, 2016

Advertisement

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Animal Testing: FDA Expectations

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Points To Consider in the Review of Endovascular Treatment Devices: Japanese Regulatory View

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

FDA Perspectives

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Overview of the Clinical Trials for Atherectomy

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Introduction to the TCT 2016 Peripheral Vascular Intervention Sessions

Overview of the Clinical Trials for Drug-Coated Balloons

Japan Academia View

US Academia View

TAVR in Patients With Poor Femoral Access

Severe AS and Extreme Co-morbidities (Futile Patient?)

Management of Failing Aortic Bioprosthesis

TAVR in Patients With Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content